NCT05226871 2025-11-25Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesPfizerPhase 2 Active not recruiting35 enrolled
NCT03709680 2025-01-14Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid TumorsPfizerPhase 2 Active not recruiting128 enrolled
NCT02499120 2023-09-08Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck CancerPfizerPhase 2 Completed125 enrolled 21 charts
NCT01684215 2020-11-23A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast CancerPfizerPhase 2 Completed61 enrolled 45 charts
NCT00555906 2015-03-19An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.PfizerPhase 2 Completed53 enrolled 18 charts